Armoring CAR-T Against Solid Tumors - Takeaways - MDSpire

Armoring CAR-T Against Solid Tumors

UCLA researchers create armored CAR-T cells that show promise for treating solid tumors

  • March 17, 2026

  • 3 min

Share

  • 1

    UCLA researchers engineered CAR-T cells to block VEGF, enhancing their ability to attack solid tumors and dismantle protective microenvironments.

  • 2

    The modified CAR-T cells release a VEGF-blocking antibody locally within tumors, avoiding systemic side effects associated with traditional anti-VEGF drugs.

  • 3

    In preclinical models, armored CAR-T cells significantly outperformed standard CAR-T therapies and systemic anti-VEGF treatments in glioblastoma and ovarian cancer.

  • 4

    The engineered CAR-T therapy improved survival rates and boosted immune signaling in ovarian cancer models, while eliminating tumors in a majority of glioma cases.

  • 5

    This research indicates a shift in immunotherapy, focusing on engineering CAR-T cells to reshape tumor environments for enhanced cancer treatment efficacy.

Original Source(s)

Armoring CAR-T Against Solid Tumors

  • March 17, 2026

Related Content

Clinical heterogeneity and treatment optimization in anti-KLHL11 encephalitis: two case reports and literature review

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
Ultraviolet radiation as a double-edged regulator of melanocyte function in vitiligo therapy and melanoma carcinogenesis